RNA therapy brings new hope for the treatment of liver cancer

British biotechnology company MiNA Therapeutics ‘innovative RNA therapy may enhance liver cancer patients’ response to standard treatment. The therapy uses a double-stranded RNA that can activate a target gene called CEBPA. Packaging double-stranded RNA in lipid nanoparticles helps to penetrate into liver cells that are often difficult to reach and can control gene expression in the nucleus. It is understood that the low level expression of certain genes is related to liver cancer and other liver diseases. In laboratory studies, increasing the expression of CEBPA to restore its protein levels to normal can help reduce the growth of cancer cells.

Among the patients receiving biotechnological small activated RNA (saRNA), two of them showed a complete response after receiving sorafenib, and the other showed a partial response after treatment with lenvatinib. This is the first trial of saRNA therapy in humans. Since the research is still in its early stages, biotech companies now hope to gather more relevant evidence.

The company also hopes to conduct the same drug test in patients with cirrhosis in the future, and also cooperates with Boehringer Ingelheim to carry out other projects for liver diseases. After a long period of development, more and more RNA treatments have entered the market. Unlike MiNA therapies that activate gene expression, most use RNA interference (RNAi) technology to reduce gene expression. Recently, the European Commission approved Onpattro, the first RNAi drug developed by Alnylam for the treatment of polyneuropathy.

RNA Therapy Shows Promise for Treating Liver Cancer

Susan Hau

Website |  + postsBio ⮌

Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.

Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.

Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.

Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.

These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.

Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.

• Susan Hau

  https://cancerfax.com/author/susan/

  Datopotamab deruxtecan-dlnk is approved by the USFDA for EGFR-mutated non-small cell lung cancer
• Susan Hau

  https://cancerfax.com/author/susan/

  PiggyBac Transposon System: A Revolutionary Tool in Cancer Gene Therapy
• Susan Hau

  https://cancerfax.com/author/susan/

  Neoadjuvant and adjuvant pembrolizumab is approved by the USFDA for resectable locally advanced head and neck squamous cell carcinoma
• Susan Hau

  https://cancerfax.com/author/susan/

  Taletrectinib is approved by the USFDA for ROS1-positive non-small cell lung cancer

• Comments Closed
• April 8th, 2020